What is ROCKET PHARMACEUTICALS INC's earnings per share (EPS)?

ROCKET PHARMACEUTICALS INC (RCKTW) reported diluted earnings per share of $-2.01 for fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ROCKET PHARMACEUTICALS INC Financials

RCKTW

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows ROCKET PHARMACEUTICALS INC (RCKTW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of ROCKET PHARMACEUTICALS INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

ROCKET PHARMACEUTICALS INC carries a low D/E ratio of 0.19, meaning only $0.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.38, ROCKET PHARMACEUTICALS INC holds $6.38 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

ROCKET PHARMACEUTICALS INC generates a -80.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -55.9% the prior year.

Piotroski F-Score Weak

1/9

ROCKET PHARMACEUTICALS INC passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, ROCKET PHARMACEUTICALS INC generates $0.85 in operating cash flow (-$190.0M OCF vs -$223.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-122.6x

ROCKET PHARMACEUTICALS INC earns $-122.6 in operating income for every $1 of interest expense (-$231.7M vs $1.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

ROCKET PHARMACEUTICALS INC generated $0 in revenue in fiscal year 2025.

EBITDA

-$222.8M

YoY+16.2%

ROCKET PHARMACEUTICALS INC's EBITDA was -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.2% from the prior year.

Net Income

-$223.1M

YoY+13.8%

ROCKET PHARMACEUTICALS INC reported -$223.1M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.

EPS (Diluted)

$-2.01

YoY+26.4%

ROCKET PHARMACEUTICALS INC earned $-2.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 26.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$190.5M

YoY+11.7%

ROCKET PHARMACEUTICALS INC generated -$190.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.7% from the prior year.

Cash & Debt

$77.6M

YoY-52.6%

5Y CAGR-23.6%

10Y CAGR-0.3%

ROCKET PHARMACEUTICALS INC held $77.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

108M

YoY+1.8%

5Y CAGR+12.2%

ROCKET PHARMACEUTICALS INC had 108M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-80.5%

YoY-24.6pp

5Y CAGR-52.8pp

10Y CAGR+357.0pp

ROCKET PHARMACEUTICALS INC's ROE was -80.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 24.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$142.0M

YoY-17.1%

5Y CAGR+6.1%

10Y CAGR+27.5%

ROCKET PHARMACEUTICALS INC invested $142.0M in research and development in fiscal year 2025. This represents a decrease of 17.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$440K

YoY-92.5%

5Y CAGR-53.7%

10Y CAGR+0.7%

ROCKET PHARMACEUTICALS INC invested $440K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 92.5% from the prior year.

RCKTW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$142.0M-17.1%	$171.2M-8.1%	$186.3M+12.5%	$165.6M+32.0%	$125.5M+19.0%	$105.4M
SG&A Expenses	$86.5M-15.2%	$102.0M+39.1%	$73.3M+24.7%	$58.8M+40.7%	$41.8M+44.7%	$28.9M
Operating Income	-$231.7M+15.2%	-$273.2M-5.2%	-$259.7M-15.7%	-$224.3M-34.1%	-$167.2M-24.5%	-$134.3M
Interest Expense	$1.9M+0.3%	$1.9M+0.6%	$1.9M+0.7%	$1.9M-37.5%	$3.0M-57.3%	$7.0M
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$223.1M+13.8%	-$258.7M-5.4%	-$245.6M-10.7%	-$221.9M-31.2%	-$169.1M-21.0%	-$139.7M
EPS (Diluted)	$-2.01+26.4%	$-2.73+6.5%	$-2.92+10.4%	$-3.26-22.1%	$-2.67-6.0%	$-2.52

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$0	$0	$0	N/A	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$34.1M-20.1%	$42.7M+18.7%	$35.9M	N/A	$42.3M-8.7%	$46.3M+2.5%	$45.2M
SG&A Expenses	N/A	$18.4M-26.7%	$25.0M-12.0%	$28.4M	N/A	$27.1M-0.9%	$27.4M+23.6%	$22.1M
Operating Income	N/A	-$52.2M+26.6%	-$71.1M-10.5%	-$64.4M	N/A	-$69.4M+5.8%	-$73.7M-9.4%	-$67.4M
Interest Expense	N/A	$473K0.0%	$473K+0.2%	$472K	N/A	$471K0.0%	$471K0.0%	$471K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$50.3M+27.0%	-$68.9M-12.4%	-$61.3M	N/A	-$66.7M+4.2%	-$69.6M-12.2%	-$62.1M
EPS (Diluted)	N/A	$-0.45+27.4%	$-0.62-10.7%	$-0.56	N/A	$-0.71+4.1%	$-0.74-12.1%	$-0.66

RCKTW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$330.4M-37.4%	$527.7M-6.8%	$566.3M+2.6%	$551.8M+11.0%	$497.0M-15.9%	$590.8M
Current Assets	$192.7M-49.0%	$378.2M0.0%	$378.2M+3.9%	$364.1M-7.1%	$392.1M-19.6%	$487.3M
Cash & Equivalents	$77.6M-52.6%	$163.6M+192.7%	$55.9M-60.2%	$140.5M-39.6%	$232.7M-21.7%	$297.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M-0.1%	$39.2M+27.2%	$30.8M0.0%	$30.8M
Total Liabilities	$53.2M-17.4%	$64.5M-12.6%	$73.8M+18.7%	$62.1M+46.9%	$42.3M-51.6%	$87.3M
Current Liabilities	$30.2M-25.8%	$40.7M-16.1%	$48.5M+23.8%	$39.2M+76.7%	$22.2M-32.0%	$32.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$277.2M-40.2%	$463.2M-6.0%	$492.6M+0.6%	$489.7M+7.7%	$454.7M-9.7%	$503.5M
Retained Earnings	-$1.4B-18.3%	-$1.2B-27.0%	-$959.4M-34.4%	-$713.8M-45.1%	-$491.9M-52.4%	-$322.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$330.4M-10.2%	$368.0M-12.6%	$421.0M-10.6%	$471.1M-10.7%	$527.7M+34.0%	$393.7M-11.8%	$446.4M-10.6%	$499.4M
Current Assets	$192.7M-15.3%	$227.7M-17.9%	$277.2M-14.6%	$324.5M-14.2%	$378.2M+56.4%	$241.8M-17.4%	$292.7M-15.2%	$345.2M
Cash & Equivalents	$77.6M+2.1%	$75.9M+131.4%	$32.8M-34.1%	$49.8M-69.6%	$163.6M+149.4%	$65.6M+69.9%	$38.6M+9.4%	$35.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M
Total Liabilities	$53.2M-2.1%	$54.4M-18.6%	$66.8M+13.3%	$58.9M-8.6%	$64.5M+0.9%	$63.9M+3.5%	$61.8M+6.6%	$57.9M
Current Liabilities	$30.2M-3.1%	$31.2M-28.2%	$43.4M+22.9%	$35.3M-13.2%	$40.7M+1.8%	$40.0M+6.4%	$37.6M+14.1%	$33.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$277.2M-11.6%	$313.7M-11.4%	$354.2M-14.1%	$412.1M-11.0%	$463.2M+40.5%	$329.8M-14.3%	$384.6M-12.9%	$441.5M
Retained Earnings	-$1.4B-3.0%	-$1.4B-3.7%	-$1.3B-5.4%	-$1.3B-5.0%	-$1.2B-5.2%	-$1.2B-6.1%	-$1.1B-6.8%	-$1.0B

RCKTW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$190.0M+9.4%	-$209.7M-7.6%	-$194.9M-9.4%	-$178.1M-47.0%	-$121.2M-62.3%	-$74.6M
Capital Expenditures	$440K-92.5%	$5.9M-64.3%	$16.4M+96.6%	$8.4M+9.7%	$7.6M-63.0%	$20.6M
Free Cash Flow	-$190.5M+11.7%	-$215.6M-2.0%	-$211.4M-13.3%	-$186.5M-44.8%	-$128.8M-35.2%	-$95.2M
Investing Cash Flow	$103.8M-21.2%	$131.7M+234.3%	-$98.1M-41.5%	-$69.3M-467.7%	$18.9M+119.5%	-$96.6M
Financing Cash Flow	$148K-99.9%	$185.7M-10.9%	$208.4M+34.2%	$155.3M+312.1%	$37.7M-86.7%	$283.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0-100.0%	$72K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$34.8M+30.9%	-$50.4M-3.0%	-$49.0M+12.2%	-$55.8M-18.8%	-$46.9M+9.9%	-$52.1M+3.2%	-$53.8M+5.3%	-$56.9M
Capital Expenditures	$80K+248.1%	-$54K-208.0%	$50K-86.3%	$364K+17.8%	$309K-80.5%	$1.6M-17.7%	$1.9M-5.2%	$2.0M
Free Cash Flow	-$34.9M+30.8%	-$50.5M-3.0%	-$49.0M+12.7%	-$56.2M-18.8%	-$47.3M+12.0%	-$53.7M+3.7%	-$55.8M+5.3%	-$58.9M
Investing Cash Flow	$36.4M-61.1%	$93.6M+194.8%	$31.8M+154.7%	-$58.0M-53.2%	-$37.9M-148.0%	$78.9M+41.9%	$55.6M+58.8%	$35.0M
Financing Cash Flow	$0+100.0%	-$67K-131.2%	$215K	$0-100.0%	$182.8M+103791.5%	$176K-88.5%	$1.5M+29.2%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCKTW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-80.5%-24.6pp	-55.9%-6.0pp	-49.9%-4.5pp	-45.3%-8.1pp	-37.2%-9.4pp	-27.7%
Return on Assets	-67.5%-18.5pp	-49.0%-5.7pp	-43.4%-3.2pp	-40.2%-6.2pp	-34.0%-10.4pp	-23.6%
Current Ratio	6.38-2.9	9.30+1.5	7.80-1.5	9.29-8.4	17.69+2.7	14.94
Debt-to-Equity	0.19+0.1	0.14-0.0	0.15+0.0	0.13+0.0	0.09-0.1	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-16.1%+3.4pp	-19.5%-4.6pp	-14.9%	N/A	-20.2%-2.1pp	-18.1%-4.1pp	-14.1%
Return on Assets	N/A	-13.7%+2.7pp	-16.4%-3.4pp	-13.0%	N/A	-17.0%-1.4pp	-15.6%-3.2pp	-12.4%
Current Ratio	6.38-0.9	7.30+0.9	6.39-2.8	9.19-0.1	9.30+3.2	6.05-1.7	7.79-2.7	10.47
Debt-to-Equity	0.19+0.0	0.17-0.0	0.19+0.0	0.140.0	0.14-0.1	0.19+0.0	0.16+0.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is ROCKET PHARMACEUTICALS INC's annual revenue?

ROCKET PHARMACEUTICALS INC (RCKTW) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is ROCKET PHARMACEUTICALS INC profitable?

No, ROCKET PHARMACEUTICALS INC (RCKTW) reported a net income of -$223.1M in fiscal year 2025.

What is ROCKET PHARMACEUTICALS INC's EBITDA?

ROCKET PHARMACEUTICALS INC (RCKTW) had EBITDA of -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is ROCKET PHARMACEUTICALS INC's return on equity (ROE)?

ROCKET PHARMACEUTICALS INC (RCKTW) has a return on equity of -80.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ROCKET PHARMACEUTICALS INC's free cash flow?

ROCKET PHARMACEUTICALS INC (RCKTW) generated -$190.5M in free cash flow during fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ROCKET PHARMACEUTICALS INC's operating cash flow?

ROCKET PHARMACEUTICALS INC (RCKTW) generated -$190.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are ROCKET PHARMACEUTICALS INC's total assets?

ROCKET PHARMACEUTICALS INC (RCKTW) had $330.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ROCKET PHARMACEUTICALS INC's capital expenditures?

ROCKET PHARMACEUTICALS INC (RCKTW) invested $440K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ROCKET PHARMACEUTICALS INC spend on research and development?

ROCKET PHARMACEUTICALS INC (RCKTW) invested $142.0M in research and development during fiscal year 2025.

How many shares does ROCKET PHARMACEUTICALS INC have outstanding?

ROCKET PHARMACEUTICALS INC (RCKTW) had 108M shares outstanding as of fiscal year 2025.

What is ROCKET PHARMACEUTICALS INC's current ratio?

ROCKET PHARMACEUTICALS INC (RCKTW) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.

What is ROCKET PHARMACEUTICALS INC's debt-to-equity ratio?

ROCKET PHARMACEUTICALS INC (RCKTW) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ROCKET PHARMACEUTICALS INC's return on assets (ROA)?

ROCKET PHARMACEUTICALS INC (RCKTW) had a return on assets of -67.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ROCKET PHARMACEUTICALS INC's cash runway?

Based on fiscal year 2025 data, ROCKET PHARMACEUTICALS INC (RCKTW) had $77.6M in cash against an annual operating cash burn of $190.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is ROCKET PHARMACEUTICALS INC's Piotroski F-Score?

ROCKET PHARMACEUTICALS INC (RCKTW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ROCKET PHARMACEUTICALS INC's earnings high quality?

ROCKET PHARMACEUTICALS INC (RCKTW) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ROCKET PHARMACEUTICALS INC cover its interest payments?

ROCKET PHARMACEUTICALS INC (RCKTW) has an interest coverage ratio of -122.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ROCKET PHARMACEUTICALS INC?

ROCKET PHARMACEUTICALS INC (RCKTW) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.